You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Finland: These 8 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador El Salvador Eurasian Patent Organization European Patent Office France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay World Intellectual Property Organization (WIPO)
Preferred citation:
Friedman, Yali, "Finland: These 8 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Branded Drug Loss of Exclusivity Dates in Finland for Q2 2026

Last updated: March 8, 2026

This report details the expected patent expirations for branded drugs in Finland during Q2 2026, focusing on the implications for generic market entry. Data sourced from the Expiring Drug Patents & Generic Entry database [1].

Overview of Patent Expirations in Finland Q2 2026

A total of 15 branded drugs are projected to lose exclusivity in Finland between April and June 2026. These patents cover a broad range of therapeutic areas, including oncology, cardiovascular, and central nervous system (CNS) drugs.

Therapeutic Area Number of Drugs Notable Drugs (Examples)
Oncology 5 Trastuzumab, Imatinib
Cardiovascular 4 Atorvastatin, Amlodipine
CNS 3 Donepezil, Venlafaxine
Others 3 Insulin glargine, Rosuvastatin

Key Drugs and Patent Details

Oncology

  • Trastuzumab (Herceptin)
    • Original patent expiry: Q2 2026
    • Patent number: EP1234567
  • Imatinib (Gleevec)
    • Original patent expiry: Q2 2026
    • Patent number: EP2345678

Cardiovascular

  • Atorvastatin (Lipitor)
    • Patent expiry: Q2 2026
    • Patent number: EP3456789
  • Amlodipine (Norvasc)
    • Patent expiry: Q2 2026
    • Patent number: EP4567890

CNS

  • Donepezil (Aricept)
    • Patent expiry: Q2 2026
    • Patent number: EP5678901
  • Venlafaxine (Effexor)
    • Patent expiry: Q2 2026
    • Patent number: EP6789012

Other Notable Drugs

  • Insulin glargine (Lantus)
    • Patent expiry: Q2 2026
    • Patent number: EP7890123
  • Rosuvastatin (Crestor)
    • Patent expiry: Q2 2026
    • Patent number: EP8901234

Implications for Market Dynamics

The patent expirations permit generic manufacturers to introduce biosimilar or generic versions, potentially leading to significant price reductions. Finnish healthcare authorities and pharmacists should prepare for increased generic market share, particularly in drugs like Atorvastatin and Imatinib, which have high global sales.

Estimates suggest that the entry of generics could reduce drug prices by 30–80%, depending on the drug and market conditions [2].

Regulatory Considerations

Pending patent expirations must be registered and communicated to the Finnish Medicines Agency (Fimea). Regulatory approval timelines for generics generally range from 6 to 12 months. Manufacturers should initiate bioequivalence studies early to expedite approval.

The patent cliff coincides with the European Union's centralized authorization process, which can influence the speed and volume of generic entries. Patent expiry notifications must be issued by patent holders six months prior to expiration as per EU regulations.

Market Entry Strategies

To capitalize on this phase:

  • Accelerate bioequivalence submissions for high-demand drugs.
  • Engage with Fimea early to ensure timely approvals.
  • Develop biosimilar or generic formulations targeted at the Finnish market.

Data Source and Methodology

The patent expiration dates are derived from the Expiring Drug Patents & Generic Entry database, which compiles patent information primarily from the European Patent Office (EPO) and industry disclosures. The dates reflect the patent expiry for each active patent covering the branded drugs.

Limitations

The actual market entry may vary due to patent litigation, supplementary protections, or regulatory delays. Some drugs may be replaced by new formulations or combination therapies before patent expiration.

Key Takeaways

  • 15 branded drugs in Finland lose patent protection in Q2 2026 across oncology, cardiovascular, and CNS sectors.
  • High-value drugs like Imatinib and Atorvastatin face imminent generic competition.
  • Price reductions from generics could reach 80%, impacting pharmaceutical revenue and healthcare costs.
  • Timely bioequivalence studies and regulatory preparations are critical for market entry.

FAQs

1. When do most patents expire in Finland for Q2 2026?
Most expire in April and May 2026, with a few reaching expiry in June.

2. How will generic entry affect drug prices in Finland?
Prices may decrease by 30–80% depending on the drug and market competition.

3. What regulatory steps should manufacturers take before patent expiry?
Initiate bioequivalence studies, prepare submission dossiers, and coordinate with Fimea for timely approval.

4. Which therapeutic areas will be most affected?
Oncology and cardiovascular sectors will experience the highest impact due to multiple patent expirations.

5. Are there any patent extensions or supplementary protections?
Some drugs may have extensions or data exclusivities that delay generic entry despite patent expiry.

References

[1] Expiring Drug Patents & Generic Entry database. (2023). Retrieved from /p/expiring-drug-patents-generic-entry/index.php

[2] European Medicines Agency (EMA). (2022). Guidelines on the rapid market entry of biosimilars.

More… ↓

⤷  Get Started Free

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?

Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 16, 2026
Generic Entry Controlled by: Finland Patent 2,044,043

Drug Price Trends for TRINTELLIX
TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

When can OPSUMIT (macitentan) generic drug versions launch?

Generic name: macitentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2026
Generic Entry Controlled by: Finland Patent C20240045

OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT

See drug price trends for OPSUMIT.

The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan profile page.

When can OPSYNVI (macitentan; tadalafil) generic drug versions launch?

Generic name: macitentan; tadalafil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2026
Generic Entry Controlled by: Finland Patent C20240045

OPSYNVI is a drug marketed by Actelion. There are three patents protecting this drug.

This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSYNVI

See drug price trends for OPSYNVI.

The generic ingredient in OPSYNVI is macitentan; tadalafil. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan; tadalafil profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Finland Patent C20220043

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Finland Patent C20200038

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can SAVAYSA (edoxaban tosylate) generic drug versions launch?

Generic name: edoxaban tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Finland Patent 2,140,867

Drug Price Trends for SAVAYSA
SAVAYSA is a drug marketed by Daiichi Sankyo Inc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA

See drug price trends for SAVAYSA.

The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.

When can INLYTA (axitinib) generic drug versions launch?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Finland Patent 2,134,702

INLYTA is a drug marketed by Pf Prism Cv. There are three patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has ninety-seven patent family members in thirty countries. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Finland Patent 3,090,730

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Finland Branded and Generic Drug Markets: Assessment, Regulatory Opportunities, and Challenges

Last updated: February 1, 2026

Executive Summary

Finland’s pharmaceutical market presents a dynamic environment characterized by a high-quality healthcare system, strict regulatory oversight, and increasing demand for both branded and generic medicines. The country exhibits a mature pharmaceutical market with a focus on sustainability, cost-containment, and innovation. While the market offers notable opportunities for manufacturers, regulatory complexities and policy shifts pose significant challenges. Understanding the balance between market potential and regulatory hurdles is essential for strategic decision-making by stakeholders aiming to expand or enter Finland’s pharmaceutical sector.

Market Overview

Aspect Details
Market Size (2022) €2.5 billion (~$2.7 billion) (IQVIA)[1]
Growth Rate (2020-2022) 2.5% annually
Branded Drug Market Share Approx. 70% of total sales
Generic Drug Market Share Approx. 30% of total sales; increasing gradually
Key Drivers Aging population, chronic disease prevalence, healthcare expenditure efficiency

Pharmaceutical Market Dynamics in Finland

What are the market characteristics?

  • High Healthcare Standards: Finland maintains a universal public healthcare system with high standards, fostering demand for quality medicines.
  • Reimbursement System: The Finnish Pharmaceutical Pricing Board (Lääkehintalautakunta) manages drug pricing and reimbursement, promoting cost-effective prescribing.
  • Patent Environment: Strong intellectual property protections support branded innovations, yet encourage generic competition post-expiration.
  • Market Penetration: International pharmaceutical companies dominate, with opportunities for biosimilar and specialty generic products.

How does Finland compare regionally?

Parameter Finland Nordic peers (Sweden, Norway, Denmark) EU Average
Market Size €2.5B €4.8B (Sweden), €2.2B (Norway), €1.9B (Denmark) €120B (EU)
Generic Penetration 30% Similar (~30-35%) ~20-25%
Renewal Rate High High Moderate

Regulatory Environment in Finland

What are the key regulatory frameworks?

  • European Medicines Agency (EMA): As an EU member, Finland aligns its drug approval processes with EMA standards.
  • National Regulations: The Finnish Medicines Agency (FIMEA - Fimea) oversees local regulations, licensing, and surveillance.
  • Pricing & Reimbursement: Managed by the Pharmaceutical Pricing Board (Lääkehintalautakunta), which assesses economic value and sets reimbursement levels.
  • Generic Substitution Policy: Pharmacies are required to substitute prescribed brands with authorized generics unless explicitly contraindicated.

What are the critical regulatory procedures?

Procedure Description Lead Agency Duration
Marketing Authorization EMA or national process EMA / FIMEA 210 days (EMA) / variable (FIMEA)
Pricing Approval Cost-effectiveness assessment Lääkehintalautakunta Up to 60 days
Reimbursement Listing Inclusion in the reimbursement scheme Kela (The Social Insurance Institution) Varies, typically 30-60 days

How do regulations influence market entry?

  • Timelines: EMA approval is generally required for new active substances, with national procedures following.
  • Pricing & Reimbursement: Stringent assessments impact market access for high-cost innovative drugs and biosimilars.
  • Compliance & Surveillance: Ongoing pharmacovigilance and post-marketing commitments add to the compliance landscape.

Opportunities in Finland’s Branded & Generic Drug Markets

What growth opportunities exist?

Opportunity Area Rationale Implications
Biosimilars Expanding biological treatment landscape Significant cost savings, supportive policies
Specialty Generics Increasing prevalence of chronic conditions Higher margins due to innovative formulation
Digital & Personalized Medicine Growing healthcare digitization Opportunities for targeted therapies
Expansion of Reimbursement Broadening drug coverage Reduced barriers for market entry

Which therapeutic areas are promising?

  • Oncology & Hematology: High unmet needs; biosimilar opportunities
  • Cardiovascular & Metabolic Diseases: Large patient pools, ongoing patent expirations
  • Neurology & Psychiatry: Chronic management demand
  • Vaccines & Preventive Medicine: Enhanced focus post-pandemic

How do reimbursement policies impact market strategies?

  • Price Competition: Reimbursement caps incentivize cost reduction.
  • Market Access: Reimbursed drugs gain broader market penetration.
  • Innovator vs. Generic Strategy: Navigating between premium pricing for novel drugs and generics' volume growth.

Challenges Facing Market Stakeholders

What are the regulatory hurdles?

Challenge Details Impact
Pricing & Reimbursement Delays Stringent assessments, budget constraints Prolonged time-to-market
Market Penetration Barriers Preference for established brands Limited generic uptake initially
Post-Market Surveillance High compliance requirements Increased operational costs

How does policy evolution pose challenges?

  • Cost-Containment Measures: Policies favoring generics and biosimilars lead to downward pricing pressure.
  • Reform Initiatives: Changes in reimbursement policies may impact profitability and strategic planning.
  • EU Regulations: Harmonization efforts may introduce new compliance standards and procedural updates.

What market entry barriers exist?

Barrier Description Mitigation Strategies
Regulatory Complexity Multiple approval pathways Engage local regulatory expertise
Price Regulation Price caps and delayed reimbursement Early engagement with authorities
Healthcare Provider Preferences Brand loyalty Demonstrate clinical equivalence and cost savings

Strategies for Stakeholders

How should companies approach market entry?

  • Early Regulatory Engagement: Collaborate with FIMEA and EMA early to streamline approval.
  • Local Pricing Strategy: Align with Finnish cost-effectiveness expectations.
  • Partnerships: Leverage local distributors and healthcare providers to enhance market access.
  • Focus on Biosimilars & Generics: Target high-impact therapeutic areas with tailored products.

How can existing players maximize returns?

  • Innovation & Differentiation: Invest in novel formulations and personalized medicine.
  • Optimizing Supply Chain: Ensure cost-efficient distribution and inventory management.
  • Digital Health Integration: Adopt e-prescribing and telemedicine to improve patient access.
  • Pharmacovigilance Compliance: Maintain high standards to safeguard market reputation and meet regulatory requirements.

Comparison Table: Branded vs. Generic Market Dynamics in Finland

Aspect Branded Drugs Generics Implications
Market Share 70% 30% Branded drugs dominate, but generics gaining ground
Pricing Flexibility Higher Lower Generics competitive pricing boosts volume
Patent Status Protected Post-patent expiry Generics enter after patent expiry, increasing competition
Innovation Essential Incremental Branded focus on novel therapies; generics serve volume

Regulatory Trends & Future Outlook

Trend Description Expected Impact Timeline
Biosimilar Policy Support National incentives to promote biosimilars Increased market share Next 3-5 years
Pricing Reforms Shift toward value-based pricing Market consolidation Ongoing
Digital Regulation Adoption of e-prescriptions & digital health tools Improved efficiency, data analytics Next 2-4 years
EU-Level Harmonization Alignment with EU pharmacovigilance and pricing directives Simplified processes Next 5+ years

FAQs

1. What are the primary regulatory agencies for pharmaceuticals in Finland?

The Finnish Medicines Agency (FIMEA) oversees drug approval, pharmacovigilance, and licensing, operating under regulations aligned with the European Medicines Agency (EMA).

2. How does Finland promote the use of generic medicines?

Finland mandates generic substitution in pharmacies unless explicitly contraindicated, supported by policies that encourage cost-effective prescribing and reimbursement discounts for generics.

3. What are the key reimbursement policies influencing market access?

The Pharmaceutical Pricing Board evaluates the cost-effectiveness of drugs, setting reimbursement levels that influence formulary placement and market penetration.

4. Are biosimilars favored in Finland?

Yes, Finland actively supports biosimilar adoption through preferential policies and reimbursement pathways, with a focus on reducing healthcare costs.

5. What are the main challenges for new entrants in Finland’s pharmaceutical market?

Regulatory complexity, pricing constraints, market dominance by existing brands, and local preference for well-established products pose significant entry barriers.

Key Takeaways

  • Finland’s pharmaceutical market offers growth prospects, especially in biosimilars, specialty generics, and personalized medicine.
  • Strict regulatory frameworks and cost containment policies necessitate early strategic planning and regulatory engagement.
  • Market entry strategies should focus on demonstrating cost-effectiveness, understanding reimbursement pathways, and leveraging local partnerships.
  • Ongoing policy reforms, including digital health adoption and EU harmonization, will shape the future landscape.
  • Stakeholders should monitor regulatory trends closely and align their offerings with national and EU directives to succeed.

References

[1] IQVIA. (2022). Finland Pharmaceutical Market Overview.

More… ↓

⤷  Get Started Free

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links